High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)

Mauro, Fr; Molica, S; Soddu, S; Ilariucci, F; Coscia, M; Zaja, F; Angelucci, E; F, Re; Liberati, Am; Tedeschi, A; Reda, G; Pietrasanta, D; Gozzetti, A; Battistini, R; Del Poeta, G; Musolino, C; Nanni, M; Piciocchi, A; Vignetti, M; Neri, A; Albano, F; Cuneo, A; Del Giudice, I; Della Starza, I; De Propris Ms,; Raponi, S; Guarini, Ar; Foà, R.

doi:10.3324/haematol.2019.235705

N/A

High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) / Mauro, F.r., Molica, S., Soddu, S., Ilariucci, F., Coscia, M., Zaja, F., Angelucci, E., Re, F., Liberati, A.m., Tedeschi, A., Reda, G., Pietrasanta, D., Gozzetti, A., Battistini, R., Del Poeta, G., Musolino, C., Nanni, M., Piciocchi, A., Vignetti, M., Neri, A., et al.. - In: HAEMATOLOGICA. - ISSN 0390-6078. - STAMPA. - 105:11(2020), pp. 2671-2674. [10.3324/haematol.2019.235705]